aguosis, especially as there were 25% reverting to normal glucose tolerance. This reversion would appear to be due to natural fluctuations in glucose concentrations, and not to be due to a change in diet or medication, as the men had no knowledge about the results of their initial examination.
Our data, from the Paris Prospective Study [3] , are shown in Table 1 . This study involved 44-55 year-old working men, the time between the two 75 g OGTFs was on average two and a half years (between 1.2 and 4.3 years), and the WHO criteria [2] were used to define IGT and diabetes. The second OGTT was not performed on those who had been identified as being diabetic by their general practitioner, before the second OGTI'. There were 26 (0.5%) such new diabetic patients from those classed normal glucose tolerant, 12 (2%) from those classed IGT and 15 (12%) from those classed diabetic on the first OGTT. Our results are strikingly similar to those of the Swedish study, both in those diagnosed IGT and those diagnosed diabetic at the first examination, despite the different time delays between tests, and the different glucose loads used.
The results on the diagnosis of IGT are similar to those reviewed by Yudkin et al. [4] : for subjects having a repeated OGTT within one year, 21-56% remained IGT, and 3-16% developed diabetes; for an OGTT repeated within 1 to 12 years, between 20-50% remained IGT, 10-47% became diabetic. Yudkin et at. suggested that insulin should be measured in IGT subjects, to discriminate between those who deteriorate to diabetes who have a failing Beta-ceil function, and those who remain IGT, with persistent hyperinsulinaemia. Two reports on the risk factors for deterioration of IGT subjects to diabetes, have shown that such IGT subjects already have a diminished 2 h insulin response to a glucose load [5, 6] . The second of these reports was on the Paris Prospective Study. If we Iook at this idea in a very simplistic, univariate fashion for the 100 subjects in the Paris Prospective Study who were initially diagnosed as diabetic by the OGTT, this trend was also apparent, though the difference was not always significant. For fasting insulin concentrations: 155_+ 20 pmol/1 (mean _+ SEM) for those reverting to ]GT, 146 _+ 14 pmol/l for those remaining diabetic, NS for the 2 h insulin concentrations: 609 + 59 pmol/1 for those reverting to IGT, 437 _+ 41 pmol/l for those remaining diabetic, p < 0.01.
The measurement of blood glucose is itself subject to analytic error [7] . Depending on the laboratory method used, the coefficient of variation can be as high as 8%, thus a concentration of 8 retool/1 lies somewhere between 6.7 and 9.3 mmol/1 with a probability of 95%.
The most recent 'Position Statement' on the screening for diabetes, from the American Diabetes Association [8] suggested that the risk factors of the individual should be used concurrently with their glucose tolerance. These risk factors are (1) family history of diabetes (2) obesity (3) race (4) age (5) previous diagnosis of IGT (6) hypertension or significant hyperlipidaemia. In the Paris Prospective Study, for the group initially classed IGT, none of the mean 
Proinsulin conversion intermediates: a possible source of confusion
Dear Sir, In their recent paper [1] , Yudkin et al. describe the measurement of proinsulin, insulin and a major proinsulin conversion intermediate in the circulation of Type 2 (non-insulin-dependent) diabetic subjects. May I draw the attention of your readers to a possible source of confusion with regard to the identity of the conversion intermediate, in both the title and the text of this paper. Throughout this and previous papers [2, 3] , the authors refer to "32-33 split proinsulin". Such an intermediate does indeed arise during proinsulin conversion as a result of an endoproteolytic attack C-terminal to Arg 32 (i. e. at the B-chain/C-peptide junction) [4] . It is, however, generally accepted that within Beta-cell granules (where conversion arises [5] ) residual C-terminal basic amino acids left from such an endoproteolytic event are rapidly removed by carboxypeptidase H [6, 7] . The major conversion intermediates found in the Beta cell, or indeed in the circulation, have thus been shown to be des 31,32-or des 64,65-split proinsulin (the latter being generated by cleavage at the C-peptide/A-chain junction followed by carboxypeptidase H trimming) [7, 8] . Of these two products, it is the des 31,32-form which predominates [8] .
The authors have themselves stressed [2] that their analytical technique, although indeed sensitive and specific [2] , cannot de-scriminate between split proinsulins and their didesamino derivatives. As mentioned above, it seems more than likely that they are in fact measuring des 31,32-split proinsulin (commonly referred to as des 31,32 proinsulin [7, 8] ) and not, as they imply, split 32-33 proinsulin from which it is derived. Analysis of circulating proinsulin forms by reversed phase HPLC would resolve the issue [8] . Even if their biological potencies have been shown to be similar [9] , these two intermediates are, as stressed above, discrete chemical entities reflecting different steps in the proinsulin conversion cascade. Any confusion between the two could lead to erroneous interpretation of data and is as such not simply a question of semantics. This is particularly true at a time when attention is becoming focussed on the precise molecular events involved in proinsulin processing [7, 10, 11] and on attempting to account for the hyperproinsulinaemia frequently encountered in diabetic states [1, 3, [12] [13] [14] [15] .
Yours sincerely, E A. Halban
